Antibody-drug conjugates (ADCs) are one of the fastest growing areas of targeted cancer therapies. These drugs contain an antibody linked to a cell-killing small molecule. Their therapeutic success depends on balancing these three components during synthesis.

In this white paper, you’ll learn about approaches to ADC preparation, the potential for enhanced target specificity with antibodies carrying PROTACs, and how partnerships with CDMOs support continued innovation for this class of compounds.